| Online-Ressource |
Verfasst von: | Penack, Olaf [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Ajib, Salem [VerfasserIn]  |
| Ayuk, Francis [VerfasserIn]  |
| Baermann, Ben-Niklas [VerfasserIn]  |
| Bug, Gesine [VerfasserIn]  |
| Kriege, Oliver [VerfasserIn]  |
| Jentzsch, Madlen [VerfasserIn]  |
| Kobbe, Guido [VerfasserIn]  |
| Koenecke, Christian [VerfasserIn]  |
| Lutz, Mathias [VerfasserIn]  |
| Martin, Sonja [VerfasserIn]  |
| Schlegel, Paul-Gerhard [VerfasserIn]  |
| Schroers, Roland [VerfasserIn]  |
| von Tresckow, Bastian [VerfasserIn]  |
| Vucinic, Vladan [VerfasserIn]  |
| Subklewe, Marion [VerfasserIn]  |
| Bethge, Wolfgang [VerfasserIn]  |
| Wolff, Daniel [VerfasserIn]  |
Titel: | Management of patients undergoing CAR-T cell therapy in Germany |
Verf.angabe: | Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff |
E-Jahr: | 2024 |
Jahr: | March 2024 |
Umfang: | 10 S. |
Fussnoten: | Online veröffentlicht: 10. Januar 2024 ; Gesehen am 13.09.2024 |
Titel Quelle: | Enthalten in: Oncology research and treatment |
Ort Quelle: | Basel : Karger, 2014 |
Jahr Quelle: | 2024 |
Band/Heft Quelle: | 47(2024), 3 vom: März, Seite 65-75 |
ISSN Quelle: | 2296-5262 |
Abstract: | Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. |
DOI: | doi:10.1159/000536201 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1159/000536201 |
| DOI: https://doi.org/10.1159/000536201 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 190252263X |
Verknüpfungen: | → Zeitschrift |
Management of patients undergoing CAR-T cell therapy in Germany / Penack, Olaf [VerfasserIn]; March 2024 (Online-Ressource)